Multiple Myeloma Gene-Edited Cell Lines for Drug Discovery

Multiple myeloma (MM) is the second most common hematologic malignancy, with an estimated 35,780 new cases and 12,540 deaths in the United States in 2024 (NCI SEER). The global age-standardized incidence rate is approximately 1.8 per 100,000 (WHO GLOBOCAN 2022). Despite therapeutic advances, the 5-year relative survival rate remains around 60% for all stages, dropping to 55% for distant-stage disease (NCI SEER 2014-2020). Key risk factors include age (median diagnosis at 69), male sex, African ancestry, obesity, and monoclonal gammopathy of undetermined significance (MGUS).

Multiple myeloma is an ideal model for mechanistic studies due to its well-characterized clonal evolution, dependence on the bone marrow microenvironment, and frequent mutations in the MAPK, NF-kB, and DNA repair pathways. Public datasets from the Multiple Myeloma Research Foundation (MMRF) CoMMpass study, TCGA, and DepMap provide extensive genomic, transcriptomic, and drug sensitivity data. Open questions include the role of clonal heterogeneity in drug resistance, the function of non-coding mutations, and the mechanisms of immune evasion.

The pathogenesis of multiple myeloma involves a multi-step process:

1. Initiation: Primary translocations involving the immunoglobulin heavy chain locus (e.g., t(11;14), t(4;14), t(14;16)) lead to oncogene activation (CCND1, FGFR3/MMSET, MAF).

2. Progression: Secondary events include RAS mutations (KRAS, NRAS), TP53 inactivation, and MYC deregulation.

3. Clonal evolution: Darwinian selection under therapeutic pressure drives emergence of resistant subclones.

4. Microenvironment interactions: Adhesion to bone marrow stromal cells activates NF-kB and JAK/STAT signaling, promoting survival and drug resistance.

Data from TCGA (Cancer Genome Atlas Research Network, 2014) and COSMIC (v99).

Key signaling networks in multiple myeloma include:

• • MAPK/ERK pathway: Activated by RAS and BRAF mutations, driving proliferation.
• • PI3K/AKT/mTOR pathway: Frequently activated via PTEN loss or PIK3CA mutations, promoting survival.
• • NF-kB pathway: Constitutive activation via mutations in TRAF3, CYLD, or BIRC2/3, enhancing anti-apoptotic gene expression.
• • JAK/STAT3 pathway: Activated by IL-6 from the microenvironment, supporting growth and drug resistance.
• • WNT/beta-catenin pathway: Deregulated in a subset of patients, contributing to self-renewal.

Organoid models derived from patient bone marrow aspirates better recapitulate the 3D architecture and microenvironment interactions, but are more technically challenging and less scalable than cell lines.

• • Patient-derived xenograft (PDX) models: Engraftment of primary MM cells into immunodeficient mice (e.g., NSG). Preserves tumor heterogeneity and microenvironment interactions.
• • Genetically engineered mouse models (GEMM): Vk*MYC model (spontaneous MM with MYC activation) and Eμ-XBP1s model. Useful for studying early disease and immune interactions.
• • Induced models: Injection of MM cell lines (e.g., RPMI-8226, U266) into SCID or NSG mice. Simple and reproducible, but lack tumor heterogeneity.

CRISPR/Cas9 gene editing enables the creation of isogenic cell lines with precise genetic modifications, such as TP53 knockout, KRAS G12D knock-in, or CD38 reporter lines. These models allow direct comparison of the effect of a specific mutation on a defined genetic background, eliminating confounding factors from different patient origins. Commercially available, sequence-verified gene-edited cell lines accelerate research by providing ready-to-use tools for functional validation, drug screening, and mechanistic studies. Examples include TP53-/- RPMI-8226 cells and NRAS Q61R knock-in U266 cells.

Knockout and knock-in cell lines are essential for validating candidate driver genes identified from sequencing studies. For example, TP53 knockout in RPMI-8226 cells confirmed its role in DNA damage response and drug sensitivity. Similarly, KRAS G12D knock-in in a wild-type background demonstrated its ability to activate MAPK signaling and promote proliferation. These models are also used for CRISPR-based synthetic lethality screens to identify vulnerabilities specific to mutant cells.

Isogenic pairs (e.g., wild-type vs. KRAS G12D) enable high-throughput drug screening to identify compounds that selectively kill mutant cells. Resistance models can be generated by chronic drug exposure or by introducing known resistance mutations (e.g., BTK C481S in ibrutinib-treated models). These systems are critical for understanding mechanisms of resistance and developing next-generation therapies.

CRISPR screens in isogenic cell lines can identify genes whose loss sensitizes cells to a particular drug, revealing potential biomarkers for patient stratification. For example, a genome-wide CRISPR screen in MM cells identified BCL2 as a synthetic lethal partner with MCL1 inhibition, leading to clinical trials of venetoclax in t(11;14) MM patients.